Czech Republic
AI|ffinity is a startup that focuses on molecular design using artificial intelligence and nuclear magnetic resonance. Founded in 2021 as a spin-off from Masaryk University and supported by the Central European Institute of Technology (CEITEC), the company specializes in creating innovative solutions for the pharmaceutical and biotechnology industries. By harnessing the power of NMR, AI, and Cheminformatics, AI|ffinity quantifies protein-ligand binding affinity for hit discovery and lead optimization, characterizes protein-ligand interactions, and determines protein 3D structures.
Operating from its headquarters in Brno (NMR hub), Czech Republic, with additional facilities in Prague (CADD hub), AI|ffinity aims to expedite the initial phases of drug discovery, improve success rates, and reduce costs by eliminating unnecessary experiments. Its comprehensive NMR-AI platform covers the entire target-to-lead process, while its 4D NMR-AI technology finds applications in drug design and protein engineering.
The company's focus on AI, Biopharma, Biotechnology, Health and Wellness, Life Sciences, and Pharmaceutical industries positions it in a promising sector with considerable growth potential. Although specific details about its last investment and investors are currently unavailable, AI|ffinity's unique approach and technological capabilities make it an intriguing prospect for potential investors in the rapidly evolving fields of AI and biotechnology.
